CVS Health and FTC Staff Agree to Proposed Insulin Settlement

Core Insights - CVS Health and the Federal Trade Commission (FTC) staff have proposed an agreement to settle litigation regarding insulin pricing, where the FTC accused pharmacy-benefit managers (PBMs) of artificially inflating insulin prices [2]. Group 1 - The proposed settlement aims to resolve accusations against PBMs related to insulin price inflation [2]. - Details of the agreement remain confidential as per a legal filing [2].